Search

everythinglearnresearchcommunity

for

Search:↓

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

Ganoderma lucidum may help treat enlarged prostate in rats.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

Hair loss gene linked to prostate issues.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Researchers found new potential treatments for conditions related to the androgen receptor, like male hormonal contraception, by testing thousands of compounds.

The main prostate diseases in dogs are benign growth, infections, and cancer, with various treatments ranging from drugs to surgery, but cancer treatments have limited success.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Finasteride may cause breast enlargement, low testosterone a risk factor.

Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

Ganoderma lucidum may help treat prostate cancer by blocking male hormones and slowing cancer cell growth.

Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.

Trapa bispinosa Roxb. extract may help reduce prostate size and cell growth in BPH.

Finasteride is safe for hair loss treatment and doesn't increase high-grade prostate cancer risk.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.

Finasteride treats hair loss and reduces prostate cancer risk.

The conclusion is that tritium-labeled testosterone metabolites can be made and are better converted into dihydrotestosterone in skin cells than in prostate tissue.

Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.

5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.